Mardi Dier
Known title: CFO & Executive Vice PresidentCIK: 0001574591
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Transaction History
| MDGL | ▼ Sell | Open Market | 646 | $279K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $17K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 420 | $179K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 80 | $34K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 160 | $69K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $17K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 120 | $52K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 116 | $50K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 160 | $69K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 80 | $35K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 80 | $35K | 3/6/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 40 | $18K | 3/6/2026 | View on chart |
| MDGL | ▲ Buy | Grant | 5,215 | $0 | 3/4/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,183 | $505K | 3/2/2026 | View on chart |
| MDGL | ▼ Sell | Open Market | 160 | $94K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 160 | $94K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 74 | $44K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 80 | $48K | 12/2/2025 | View on chart |
| MDGL | ▲ Buy | Option Exercise | 4,173 | $1.1M | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 320 | $183K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 410 | $235K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 354 | $203K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 717 | $412K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 120 | $69K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 240 | $138K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 320 | $185K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 258 | $149K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 480 | $278K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 240 | $141K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 240 | $141K | 12/2/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 258 | $83K | 3/10/2025 | View on chart |
| MDGL | ▲ Buy | Grant | 3,784 | $0 | 3/5/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 1,187 | $387K | 3/3/2025 | View on chart |
| MDGL | ▼ Sell | Open Market | 774 | $250K | 3/3/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 1,629 | $65K | 10/14/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 3,484 | $133K | 10/12/2022 | View on chart |
| RARE | ▲ Buy | Grant | 20,000 | $0 | 9/16/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 420 | $27K | 3/3/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 534 | $36K | 3/1/2022 | View on chart |
| RARE | ▲ Buy | Grant | 14,000 | $0 | 3/1/2022 | View on chart |
| RARE | ▼ Sell | Open Market | 3,261 | $265K | 10/14/2021 | View on chart |
| RARE | ▼ Sell | Open Market | 3,477 | $288K | 10/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data
Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.